Key result
Dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice, but did not reduce these effects or in vitro cytotoxicity from doxorubicin.
Why the study?
Does dexrazoxane reduce myelosuppression from etoposide, daunorubicin, and doxorubicin in preclinical models?
Population
Human and murine blood progenitor cells (in vitro) and B6D2F1 mice (in vivo)
Comparison
Dexrazoxane coadministered with etoposide… vs Etoposide, daunorubicin, or doxorubicin without…
Design
Preclinical
Authors
Loading...
Dexrazoxane shows agent-specific myeloprotection in mice; leaves open translation to clinical cardioprotection or antitumor activity.
Does dexrazoxane reduce myelosuppression from etoposide, daunorubicin, and doxorubicin in preclinical models?
Dexrazoxane protects against myelosuppression from daunorubicin and etoposide but not doxorubicin, though it may antagonize daunorubicin's antitumor activity.
Hofland et al. (2005) studied Myelosuppression from DNA cleavage-enhancing drugs. Dexrazoxane vs. Without dexrazoxane was evaluated on Myelosuppression and weight loss. Dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice, but did not reduce these effects or in vitro cytotoxicity from doxorubicin.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: